NCT03194542 trial:
Luspatercept for the treatment of patients with anemic myelofibrosis
Join us for an informative webinar discussing the NCT03194542 trial, focusing on the use of luspatercept for the treatment of patients with anemic myelofibrosis (MF). This webinar aims to enhance your understanding of luspatercept's mechanism of action, its application in patients with anemic MF, and the safety and efficacy data from the trial. By attending this session, you will gain insights into the role of luspatercept in the MF therapeutic landscape and how it compares to other available therapies. Additionally, there will be a live Q&A session so you can speak directly to our expert panel.
Don't miss out on this opportunity to learn more about this clinical trial.
This webinar is part of the MPN Hub clinical trial club series, Novel agents for the treatment of advanced myelofibrosis, and is brought to you by the MPN Hub and Scientific Education Support.
Agenda
CME accreditation will be provided by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC). You will receive 1 hour of external CME credit for full attendance of the webinar, including completion of the pre-/post-CME test questions and evaluation.
Welcome and introductions
Luspatercept mechanism of action
- Reduction in anemia
- Erythropoiesis
NCT03194542 trial
- Study design
- Eligibility
- Primary endpoints
Key efficacy/safety findings
- Secondary endpoints
- Quality of life
- What's missing in this trial?
- Potential exploratory analysis
Luspatercept compared with other available therapies
- How will it add to the current clinical landscape?
Q&A Session
Evaluation/close
In compliance with EBAC guidelines, all speakers/chairpersons participating in this program have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Learning objectives
Following this symposium, participants will be able to:
- Recall the mechanism of action of luspatercept
- Describe the use of luspatercept in patients with anemic MF
- Recall key safety and efficacy data from the NCT03194542 trial
- Explain the role of luspatercept in the MF therapeutic landscape
Our speakers
Meet our panel of experts
Jean-Jacques Kiladjian
Université Paris Cité
Paris, FR
Aaron Gerds
Cleveland Clinic Taussig Cancer Institute
Cleveland, US
About the MPN Hub
The MPN Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MPN. Our aim is to enhance knowledge in MPN through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.
The MPN Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.